Cargando…

Impossibility to eliminate observer effect in the assessment of adherence in clinical trials

PURPOSE: To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication adherence, while also determining whether or not altering the functionality of the DA in three randomized subject groups can reduce observer effect. METHODS: Forty-five subjects were randomized into three grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Jonathan S, Fudemberg, Scott J, Fintelmann, Robert E, Hark, Lisa A, Khanna, Nitasha, Leiby, Benjamin E, Waisbourd, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087773/
https://www.ncbi.nlm.nih.gov/pubmed/27822015
http://dx.doi.org/10.2147/PPA.S114746
_version_ 1782463969396523008
author Myers, Jonathan S
Fudemberg, Scott J
Fintelmann, Robert E
Hark, Lisa A
Khanna, Nitasha
Leiby, Benjamin E
Waisbourd, Michael
author_facet Myers, Jonathan S
Fudemberg, Scott J
Fintelmann, Robert E
Hark, Lisa A
Khanna, Nitasha
Leiby, Benjamin E
Waisbourd, Michael
author_sort Myers, Jonathan S
collection PubMed
description PURPOSE: To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication adherence, while also determining whether or not altering the functionality of the DA in three randomized subject groups can reduce observer effect. METHODS: Forty-five subjects were randomized into three groups: two with monitored DAs and one without monitoring. One group of subjects was given a DA that both monitored drop usage and had visual and audible alarms, while the other monitored group included subjects given a DA that had no alarms but continued to monitor drop usage. The third group was given a DA that had no alarm reminders or dose usage monitoring. Subjects were informed that some monitors would not be functional, in an attempt to reduce observer effect, or the effect of being monitored on subject behavior and adherence. A six-item questionnaire was also utilized to assess how the subjects felt about their adherence and DA use. RESULTS: The overall adherence rates were found to be 78% in the fully functional group (95% confidence interval: 70–88) and 76% in the no alarms group (95% confidence interval: 65–89). No association was seen between questionnaire response and medication adherence. The patients in the DA group without alarms had a significantly higher odds ratio of medication adherence if they reported on the questionnaire that using the DA did affect how much they used their drops. CONCLUSION: Though the use of DA was expected to reveal different rates of adherence depending on the functionality of the DA between groups, patients with a nonfunctioning DA did not have a significant difference in medication adherence compared to those given a fully functional DA. This supports that an observer effect was not reduced despite these interventions, and that the subjects adhered to taking their medications as if they had a functioning DA and were being monitored.
format Online
Article
Text
id pubmed-5087773
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50877732016-11-07 Impossibility to eliminate observer effect in the assessment of adherence in clinical trials Myers, Jonathan S Fudemberg, Scott J Fintelmann, Robert E Hark, Lisa A Khanna, Nitasha Leiby, Benjamin E Waisbourd, Michael Patient Prefer Adherence Original Research PURPOSE: To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication adherence, while also determining whether or not altering the functionality of the DA in three randomized subject groups can reduce observer effect. METHODS: Forty-five subjects were randomized into three groups: two with monitored DAs and one without monitoring. One group of subjects was given a DA that both monitored drop usage and had visual and audible alarms, while the other monitored group included subjects given a DA that had no alarms but continued to monitor drop usage. The third group was given a DA that had no alarm reminders or dose usage monitoring. Subjects were informed that some monitors would not be functional, in an attempt to reduce observer effect, or the effect of being monitored on subject behavior and adherence. A six-item questionnaire was also utilized to assess how the subjects felt about their adherence and DA use. RESULTS: The overall adherence rates were found to be 78% in the fully functional group (95% confidence interval: 70–88) and 76% in the no alarms group (95% confidence interval: 65–89). No association was seen between questionnaire response and medication adherence. The patients in the DA group without alarms had a significantly higher odds ratio of medication adherence if they reported on the questionnaire that using the DA did affect how much they used their drops. CONCLUSION: Though the use of DA was expected to reveal different rates of adherence depending on the functionality of the DA between groups, patients with a nonfunctioning DA did not have a significant difference in medication adherence compared to those given a fully functional DA. This supports that an observer effect was not reduced despite these interventions, and that the subjects adhered to taking their medications as if they had a functioning DA and were being monitored. Dove Medical Press 2016-10-25 /pmc/articles/PMC5087773/ /pubmed/27822015 http://dx.doi.org/10.2147/PPA.S114746 Text en © 2016 Myers et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Myers, Jonathan S
Fudemberg, Scott J
Fintelmann, Robert E
Hark, Lisa A
Khanna, Nitasha
Leiby, Benjamin E
Waisbourd, Michael
Impossibility to eliminate observer effect in the assessment of adherence in clinical trials
title Impossibility to eliminate observer effect in the assessment of adherence in clinical trials
title_full Impossibility to eliminate observer effect in the assessment of adherence in clinical trials
title_fullStr Impossibility to eliminate observer effect in the assessment of adherence in clinical trials
title_full_unstemmed Impossibility to eliminate observer effect in the assessment of adherence in clinical trials
title_short Impossibility to eliminate observer effect in the assessment of adherence in clinical trials
title_sort impossibility to eliminate observer effect in the assessment of adherence in clinical trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087773/
https://www.ncbi.nlm.nih.gov/pubmed/27822015
http://dx.doi.org/10.2147/PPA.S114746
work_keys_str_mv AT myersjonathans impossibilitytoeliminateobservereffectintheassessmentofadherenceinclinicaltrials
AT fudembergscottj impossibilitytoeliminateobservereffectintheassessmentofadherenceinclinicaltrials
AT fintelmannroberte impossibilitytoeliminateobservereffectintheassessmentofadherenceinclinicaltrials
AT harklisaa impossibilitytoeliminateobservereffectintheassessmentofadherenceinclinicaltrials
AT khannanitasha impossibilitytoeliminateobservereffectintheassessmentofadherenceinclinicaltrials
AT leibybenjamine impossibilitytoeliminateobservereffectintheassessmentofadherenceinclinicaltrials
AT waisbourdmichael impossibilitytoeliminateobservereffectintheassessmentofadherenceinclinicaltrials